Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The ENST00000357654.9(BRCA1):c.1342C>T(p.His448Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000372 in 1,613,900 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H448P) has been classified as Likely benign.
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Likely_benign. Variant got -1 ACMG points.
BP6
Variant 17-43094189-G-A is Benign according to our data. Variant chr17-43094189-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 187241.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=4, Likely_benign=2}.
Uncertain significance, criteria provided, single submitter
curation
Sema4, Sema4
Jan 18, 2022
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Aug 29, 2022
The p.H448Y variant (also known as c.1342C>T), located in coding exon 9 of the BRCA1 gene, results from a C to T substitution at nucleotide position 1342. The histidine at codon 448 is replaced by tyrosine, an amino acid with similar properties. In one study, this alteration was identified in a hereditary prostate cancer family, however it was identified in both affected and unaffected males (Zuhlke, KA et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5975-80). This variant was also identified in an individual diagnosed with breast and/or ovarian cancer (Zuntini R et al. Front Genet, 2018 Sep;9:378). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Likely benign, criteria provided, single submitter
curation
University of Washington Department of Laboratory Medicine, University of Washington
Mar 23, 2023
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Oct 03, 2019
Variant summary: BRCA1 c.1342C>T (p.His448Tyr) results in a conservative amino acid change located in the BRCA1, Serine-rich domain (IPRO25994) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250878 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1342C>T has been reported in the literature in a sequencing study of individuals affected with Prostate cancer where it was reportedly identified among some unaffected males in one bileneal family (Zuhlke_2004). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with other pathogenic variant(s) have been reported in the BIC database (BRCA2 c.7180A>T, p.Arg2394Ter), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Jun 10, 2016
- -
BRCA1-related cancer predisposition Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Jul 20, 2024
This missense variant replaces histidine with tyrosine at codon 448 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in a suspected hereditary prostate cancer family in both affected and unaffected males (PMID: 15447980). Two multifactorial analyses have reported likelihood ratios (LR) based on family history or personal and family history of 0.2799 and 0.9841 (from log(LR) = -0.006975795142), respectively (PMID: 31131967, 31853058). This variant has been identified in 2/250878 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter